{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T05:50:35Z","timestamp":1790142635274,"version":"4.0.1"},"reference-count":35,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:00:00Z","timestamp":1787011200000},"content-version":"am","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100011725","name":"Servier","doi-asserted-by":"publisher","award":["2009-2016"],"award-info":[{"award-number":["2009-2016"]}],"id":[{"id":"10.13039\/501100011725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Sex differences in the longitudinal evolution of low-density lipoprotein cholesterol (LDL-C) management among patients with chronic coronary syndromes (CCS) are not well known.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>In the international CLARIFY registry, which included patients with CCS, LDL-C levels were monitored annually over the 5-year follow-up period. The analysis included patients with available LDL-C measurement at baseline. Target LDL-C was set at 100\u2005mg\/dL, in line with prevailing recommendations at enrolment. Sex-specific differences in LDL-C were adjusted for age and geographical region. Impact of longitudinal LDL-C was assessed using mean LDL-C up to the primary outcome of interest or last follow-up, defined as cardiovascular (CV) death or MI during 5-year follow-up, evaluated using multivariable analysis. Of 32 376 patients in the initial cohort, women were less likely to have LDL-C measurement available at baseline (adjusted odds ratio [aOR] 1.12, 95% confidence interval [CI] 1.06\u20131.18, P &amp;lt; 0.001). Of the 21 925 patients with LDL-C measurement at baseline, 21.6% were women. At inclusion, women were less likely to receive statins (82.7% vs. 85.4%, P &amp;lt; 0.001) and more likely to fail reaching the LDL-C target (45.6% vs. 37.4%; aOR 1.47, 95% CI 1.38\u20131.58, P &amp;lt; 0.001). This disparity persisted across the 5-year follow-up (P &amp;lt; 0.001 for every year). Overall, women were more likely than men to never reach the target LDL-C during follow-up (20.7% vs. 15.8%; aOR 1.44, 95% CI 1.32\u20131.56, P &amp;lt; 0.001). Higher mean LDL-C during follow-up was associated with an increased risk of the primary outcome (aHR 1.06 per 10\u2005mg\/dL increase, 95% CI 1.04\u20131.07, P &amp;lt; 0.001).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Women with CCS were less likely to have LDL-C measurement available at baseline, to receive lipid-lowering drugs, and consistently exhibited poorer LDL-C control than men over the 5-year follow-up. Given the association of LDL-C and adverse CV outcomes, targeted interventions to close the sex gap in secondary prevention are needed.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/eurjpc\/zwag419","type":"journal-article","created":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T11:15:19Z","timestamp":1786965319000},"source":"Crossref","is-referenced-by-count":1,"title":["Sex differences in trajectories of LDL cholesterol control in chronic coronary syndromes"],"prefix":"10.1093","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2131-6763","authenticated-orcid":false,"given":"Jules","family":"Mesnier","sequence":"first","affiliation":[{"name":"Universit\u00e9 Paris Cit\u00e9 , Paris ,","place":["France"]},{"name":"Assistance Publique-H\u00f4pitaux de Paris, H\u00f4pital Bichat , 46 rue Henri Huchard, Paris 75018 ,","place":["France"]},{"name":"French Alliance for Cardiovascular Trials FACT\/F-CRIN and INSERM U1148\/LVTS , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis","family":"Giovachini","sequence":"additional","affiliation":[{"name":"Assistance Publique-H\u00f4pitaux de Paris, H\u00f4pital Bichat , 46 rue Henri Huchard, Paris 75018 ,","place":["France"]},{"name":"French Alliance for Cardiovascular Trials FACT\/F-CRIN and INSERM U1148\/LVTS , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4069-1128","authenticated-orcid":false,"given":"Gregory","family":"Ducrocq","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Paris Cit\u00e9 , Paris ,","place":["France"]},{"name":"Assistance Publique-H\u00f4pitaux de Paris, H\u00f4pital Bichat , 46 rue Henri Huchard, Paris 75018 ,","place":["France"]},{"name":"French Alliance for Cardiovascular Trials FACT\/F-CRIN and INSERM U1148\/LVTS , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2273-1528","authenticated-orcid":false,"given":"Gaspard","family":"Suc","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Paris Cit\u00e9 , Paris ,","place":["France"]},{"name":"Assistance Publique-H\u00f4pitaux de Paris, H\u00f4pital Bichat , 46 rue Henri Huchard, Paris 75018 ,","place":["France"]},{"name":"French Alliance for Cardiovascular Trials FACT\/F-CRIN and INSERM U1148\/LVTS , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Ferrari","sequence":"additional","affiliation":[{"name":"Maria Cecilia Hospital, Department of Cardiology and LTTA Centre, University Hospital of Ferrara and Maria Cecilia Hospital , Cotignola ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5927-1823","authenticated-orcid":false,"given":"Ian","family":"Ford","sequence":"additional","affiliation":[{"name":"Robertson Centre for Biostatistics , Glasgow ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8200-8983","authenticated-orcid":false,"given":"Jean-Claude","family":"Tardif","sequence":"additional","affiliation":[{"name":"Montreal Heart Institute, Universit\u00e9 de Montr\u00e9al , Montreal ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0812-6113","authenticated-orcid":false,"given":"Michal","family":"Tendera","sequence":"additional","affiliation":[{"name":"School of Medicine in Katowice, Medical University of Silesia , Katowice ,","place":["Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim M","family":"Fox","sequence":"additional","affiliation":[{"name":"Imperial College, Royal Brompton Hospital , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6896-2941","authenticated-orcid":false,"given":"Philippe Gabriel","family":"Steg","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Paris Cit\u00e9 , Paris ,","place":["France"]},{"name":"Assistance Publique-H\u00f4pitaux de Paris, H\u00f4pital Bichat , 46 rue Henri Huchard, Paris 75018 ,","place":["France"]},{"name":"French Alliance for Cardiovascular Trials FACT\/F-CRIN and INSERM U1148\/LVTS , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,8,18]]},"reference":[{"key":"2026091902520532200_zwag419-B1","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials","volume":"376","author":"Cholesterol Treatment Trialists\u2019 (Ctt) Collaboration","year":"2010","journal-title":"The Lancet"},{"key":"2026091902520532200_zwag419-B2","doi-asserted-by":"crossref","first-page":"7432","DOI":"10.3390\/jcm12237432","article-title":"Evolution of more aggressive LDL-cholesterol targets and therapies for cardiovascular disease prevention","volume":"12","author":"Jones","year":"2023","journal-title":"J Clin Med"},{"key":"2026091902520532200_zwag419-B3","doi-asserted-by":"crossref","first-page":"3415","DOI":"10.1093\/eurheartj\/ehae177","article-title":"2024 ESC guidelines for the management of chronic coronary syndromes","volume":"45","author":"Vrints","year":"2024","journal-title":"Eur Heart J"},{"key":"2026091902520532200_zwag419-B4","doi-asserted-by":"crossref","first-page":"e865","DOI":"10.1161\/CIR.0000000000001328","article-title":"2025 ACC\/AHA\/ACEP\/NAEMSP\/SCAI guideline for the management of patients with acute coronary syndromes: a report of the American College of Cardiology\/American Heart Association joint committee on clinical practice guidelines","volume":"151","author":"Rao","year":"2025","journal-title":"Circulation"},{"key":"2026091902520532200_zwag419-B5","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N Engl J Med"},{"key":"2026091902520532200_zwag419-B6","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"key":"2026091902520532200_zwag419-B7","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N Engl J Med"},{"key":"2026091902520532200_zwag419-B8","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1016\/j.jacc.2018.02.032","article-title":"Sex differences in high-intensity statin use following myocardial infarction in the United States","volume":"71","author":"Peters","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"2026091902520532200_zwag419-B9","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.amjcard.2014.09.041","article-title":"Gender disparities in evidence-based statin therapy in patients with cardiovascular disease","volume":"115","author":"Virani","year":"2015","journal-title":"Am J Cardiol"},{"key":"2026091902520532200_zwag419-B10","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1016\/j.amjcard.2014.02.018","article-title":"Gender differences in achieving optimal lipid goals in patients with coronary artery disease","volume":"113","author":"Victor","year":"2014","journal-title":"Am J Cardiol"},{"key":"2026091902520532200_zwag419-B11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.amjcard.2025.05.029","article-title":"Bridging gaps in LDL-C management: utilization of lipid-lowering therapies, gender disparities, and the impact of cardiology visits on secondary prevention","volume":"253","author":"Sedrakyan","year":"2025","journal-title":"Am J Cardiol"},{"key":"2026091902520532200_zwag419-B12","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1002\/clc.22730","article-title":"Rationale, design, and baseline characteristics of the CLARIFY registry of outpatients with stable coronary artery disease: CLARIFY registry of outpatients with stable CAD","volume":"40","author":"Sorbets","year":"2017","journal-title":"Clin Cardiol"},{"key":"2026091902520532200_zwag419-B13","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s41073-016-0007-6","article-title":"Sex and gender equity in research: rationale for the SAGER guidelines and recommended use","volume":"1","author":"Heidari","year":"2016","journal-title":"Res Integr Peer Rev"},{"key":"2026091902520532200_zwag419-B14","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.1161\/CIR.0b013e318235eb4d","article-title":"AHA\/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology foundation","volume":"124","author":"Smith","year":"2011","journal-title":"Circulation"},{"key":"2026091902520532200_zwag419-B15","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1093\/eurheartj\/ehm316","article-title":"European guidelines on cardiovascular disease prevention in clinical practice: executive summary: fourth joint task force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts)","volume":"28","author":"Authors\/Task Force Members","year":"2007","journal-title":"Eur Heart J"},{"key":"2026091902520532200_zwag419-B16","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1093\/eurheartj\/ehz660","article-title":"Long-term outcomes of chronic coronary syndrome worldwide: insights from the international CLARIFY registry","volume":"41","author":"Sorbets","year":"2019","journal-title":"Eur Heart J"},{"key":"2026091902520532200_zwag419-B17","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1161\/CIRCULATIONAHA.121.054567","article-title":"International observational analysis of evolution and outcomes of chronic stable angina: the multinational CLARIFY study","volume":"144","author":"Mesnier","year":"2021","journal-title":"Circulation"},{"key":"2026091902520532200_zwag419-B18","doi-asserted-by":"publisher","DOI":"10.1093\/eurjpc\/zwaf222","article-title":"Smoking trajectories and residual cardiovascular risk in patients with stable coronary artery disease: an international cohort study","author":"Mesnier","year":"2025","journal-title":"Eur J Prev Cardiol"},{"key":"2026091902520532200_zwag419-B19","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1177\/2047487315585293","article-title":"Time trends and gender differences in prevention guideline adherence and outcome after myocardial infarction: data from the SWEDEHEART registry","volume":"23","author":"Hambraeus","year":"2016","journal-title":"Eur J Prev Cardiol"},{"key":"2026091902520532200_zwag419-B20","doi-asserted-by":"crossref","first-page":"100722","DOI":"10.1016\/j.ajpc.2024.100722","article-title":"Gender disparities in utilization of statins for low density lipoprotein management across the spectrum of atherosclerotic cardiovascular disease: insights from the Houston methodist cardiovascular disease learning health system registry","volume":"19","author":"Shahid","year":"2024","journal-title":"Am J Prev Cardiol"},{"key":"2026091902520532200_zwag419-B21","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1186\/s12939-024-02230-3","article-title":"Gender inequalities in secondary prevention of cardiovascular disease: a scoping review","volume":"23","author":"L\u00f3pez Ferreruela","year":"2024","journal-title":"Int J Equity Health"},{"key":"2026091902520532200_zwag419-B22","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1161\/CIRCULATIONAHA.105.561647","article-title":"Gender differences in the management and clinical outcome of stable angina","volume":"113","author":"Daly","year":"2006","journal-title":"Circulation"},{"key":"2026091902520532200_zwag419-B23","doi-asserted-by":"crossref","first-page":"101342","DOI":"10.1016\/j.pmedr.2021.101342","article-title":"Differences between men and women in the use of preventive medications following a major cardiovascular event: australian prospective cohort study","volume":"22","author":"Barrett","year":"2021","journal-title":"Prev Med Rep"},{"key":"2026091902520532200_zwag419-B24","first-page":"e43482","article-title":"Analysis of gender-based inequality in cardiovascular health: an Umbrella review","volume":"15","author":"Bosomworth","year":"2023","journal-title":"Cureus"},{"key":"2026091902520532200_zwag419-B25","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/S0147-9563(95)80020-4","article-title":"Gender bias in the diagnosis and treatment of coronary artery disease","volume":"24","author":"Beery","year":"1995","journal-title":"Heart Lung"},{"key":"2026091902520532200_zwag419-B26","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.ahj.2024.12.011","article-title":"The under-representation of women in cardiovascular clinical trials: state-of-the-art review and ethical considerations","volume":"282","author":"Burgess","year":"2025","journal-title":"Am Heart J"},{"key":"2026091902520532200_zwag419-B27","doi-asserted-by":"crossref","first-page":"e005562","DOI":"10.1161\/CIRCOUTCOMES.118.005562","article-title":"Sex differences in the use of statins in community practice","volume":"12","author":"Nanna","year":"2019","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"2026091902520532200_zwag419-B28","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.jacl.2016.02.016","article-title":"Gender differences in side effects and attitudes regarding statin use in the understanding statin use in America and gaps in patient education (USAGE) study","volume":"10","author":"Karalis","year":"2016","journal-title":"J Clin Lipidol"},{"key":"2026091902520532200_zwag419-B29","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1016\/S0140-6736(17)31075-9","article-title":"Adverse events associated with unblinded, but not with blinded, statin therapy in the Anglo-Scandinavian cardiac outcomes trial-lipid-lowering arm (ASCOT-LLA): a randomised double-blind placebo-controlled trial and its non-randomised non-blind extension phase","volume":"389","author":"Gupta","year":"2017","journal-title":"Lancet"},{"key":"2026091902520532200_zwag419-B30","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/S0140-6736(22)01545-8","article-title":"Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomised, double-blind trials","volume":"400","author":"Cholesterol Treatment Trialists\u2019 Collaboration","year":"2022","journal-title":"Lancet"},{"key":"2026091902520532200_zwag419-B31","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1161\/CIRCULATIONAHA.116.026336","article-title":"Medical therapy for secondary prevention and long-term outcome in patients with myocardial infarction with nonobstructive coronary artery disease","volume":"135","author":"Lindahl","year":"2017","journal-title":"Circulation"},{"key":"2026091902520532200_zwag419-B32","doi-asserted-by":"crossref","first-page":"100669","DOI":"10.1016\/j.jacadv.2023.100669","article-title":"Sex differences in cardiovascular outcomes and cholesterol-lowering efficacy of PCSK9 inhibitors","volume":"2","author":"Rivera","year":"2023","journal-title":"JACC Adv"},{"key":"2026091902520532200_zwag419-B33","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1812792","article-title":"Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia","volume":"380","author":"Bhatt","year":"2019","journal-title":"N Engl J Med"},{"key":"2026091902520532200_zwag419-B34","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1056\/NEJMoa2215024","article-title":"Bempedoic acid and cardiovascular outcomes in statin-intolerant patients","volume":"388","author":"Nissen","year":"2023","journal-title":"N Engl J Med"},{"key":"2026091902520532200_zwag419-B35","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/S0140-6736(22)01441-6","article-title":"Metabolic, behavioural, and psychosocial risk factors and cardiovascular disease in women compared with men in 21 high-income, middle-income, and low-income countries: an analysis of the PURE study","volume":"400","author":"Walli-Attaei","year":"2022","journal-title":"The Lancet"}],"container-title":["European Journal of Preventive Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurjpc\/advance-article-pdf\/doi\/10.1093\/eurjpc\/zwag419\/70675313\/zwag419.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjpc\/advance-article-pdf\/doi\/10.1093\/eurjpc\/zwag419\/70675313\/zwag419.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T06:52:17Z","timestamp":1789800737000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjpc\/advance-article\/doi\/10.1093\/eurjpc\/zwag419\/8763031"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,18]]},"references-count":35,"URL":"https:\/\/doi.org\/10.1093\/eurjpc\/zwag419","relation":{},"ISSN":["2047-4873","2047-4881"],"issn-type":[{"value":"2047-4873","type":"print"},{"value":"2047-4881","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,18]]},"article-number":"zwag419"}}